Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Jason P Mendoza"'
Autor:
Tobias Sejbaek, Natasha Penner, Jason P Mendoza, Zsolt Illes, Jonna Skov Madsen, Dorte Aalund Olsen
Publikováno v:
BMJ Neurology Open, Vol 2, Iss 2 (2020)
Objectives To examine levels of neurofilament light chain (NFL) in identical cerebrospinal fluid (CSF) and blood samples at two different facilities, and how differences affect interpretation of levels within and above the normal range.Methods CSF an
Externí odkaz:
https://doaj.org/article/ca759d35bf594fb79150867cabe057e2
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-8 (2024)
Abstract Background Social risk such as housing instability, trouble affording medical care and food insecurity are a downstream effect of social determinants of health (SDOHs) and are frequently associated with worse health. SDOHs include experience
Externí odkaz:
https://doaj.org/article/b7e59785d3534510a85a15b7812b876a
Autor:
Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1273-1285 (2024)
Abstract Introduction In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in year 1, then stabilized, similar to ALC decline observed with dimethyl fumarate (DMF).
Externí odkaz:
https://doaj.org/article/8438206336ce48d6a191208930b85bc7
Publikováno v:
International Journal of Behavioral Nutrition and Physical Activity, Vol 21, Iss 1, Pp 1-11 (2024)
Abstract Background The purpose of this study was to investigate the effects of a walking school bus intervention on children’s active commuting to school. Methods We conducted a randomized controlled trial (RCT) in Houston, Texas (Year 1) and Seat
Externí odkaz:
https://doaj.org/article/0bf95facb26f406882a04aa5532ab293
Autor:
Jean A. McDougall, Katherine J. Briant, Elizabeth Carosso, Allison M. Cole, Craig Dee, David R. Doody, Peggy A. Hannon, Vida Henderson, Selisha Johnson, Myra Parker, Stephen M. Schwartz, Jason A. Mendoza
Publikováno v:
Preventive Oncology & Epidemiology, Vol 2, Iss 1 (2024)
Background: In 2022, the catchment area of the Fred Hutchinson/University of Washington/Seattle Children’s Cancer Consortium (the Consortium) grew from 13-counties in Western Washington State to include all 39 counties in Washington.Methods: Wideni
Externí odkaz:
https://doaj.org/article/7710eccba6c141a79fa03497db2e483f
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66772 (2013)
The exact mechanism of glatiramer acetate (GA, Copaxone®), an FDA-approved immunomodulatory therapy for multiple sclerosis (MS), remains unclear after decades of research. Previously, we have shown that GA therapy of MS induces CD8(+) T cell respons
Externí odkaz:
https://doaj.org/article/a1fe190c1f2e47a78d5f41c1aadaf85e
Autor:
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2199-2203 (2023)
Externí odkaz:
https://doaj.org/article/f752573b25fa4a30838db3262a5c2fdd
Autor:
Lilyana Amezcua, Yang Mao-Draayer, Wendy S. Vargas, Rebecca Farber, Sara Schaefer, Filipe Branco, Sarah M. England, Nicholas Belviso, James B. Lewin, Jason P. Mendoza, Sai L. Shankar, the ENDORSE Study Investigators
Publikováno v:
Neurology and Therapy, Vol 12, Iss 3, Pp 883-897 (2023)
Abstract Introduction Dimethyl fumarate (DMF) showed favorable benefit-risk in patients with relapsing-remitting multiple sclerosis (MS) in phase 3 DEFINE and CONFIRM trials and in the ENDORSE extension study. Disease activity can differ in younger p
Externí odkaz:
https://doaj.org/article/70917083128f4eb98cbbe4a83c3efa9c
Autor:
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay
Publikováno v:
Neurology and Therapy, Vol 12, Iss 2, Pp 687-700 (2023)
Abstract Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs. Methods
Externí odkaz:
https://doaj.org/article/eea609e5db7d4cbfa2acd727ee51ef46
Autor:
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin
Publikováno v:
Neurology and Therapy, Vol 12, Iss 1, Pp 145-159 (2022)
Abstract Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS. It has the same pharmacolog
Externí odkaz:
https://doaj.org/article/f512ef3b56f34173b2ff3a4b8030b0a5